- Home
- THQ vs MDXG Comparison
THQ vs MDXG Comparison
Compare THQ & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THQ
- MDXG
- Stock Information
- Founded
- THQ 2014
- MDXG 2006
- Country
- THQ United States
- MDXG United States
- Employees
- THQ N/A
- MDXG N/A
- Industry
- THQ Finance Companies
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- THQ Finance
- MDXG Health Care
- Exchange
- THQ Nasdaq
- MDXG Nasdaq
- Market Cap
- THQ 763.4M
- MDXG 877.4M
- IPO Year
- THQ N/A
- MDXG N/A
- Fundamental
- Price
- THQ $17.22
- MDXG $6.59
- Analyst Decision
- THQ
- MDXG Strong Buy
- Analyst Count
- THQ 0
- MDXG 2
- Target Price
- THQ N/A
- MDXG $11.50
- AVG Volume (30 Days)
- THQ 158.9K
- MDXG 939.2K
- Earning Date
- THQ 01-01-0001
- MDXG 07-30-2025
- Dividend Yield
- THQ 7.53%
- MDXG N/A
- EPS Growth
- THQ N/A
- MDXG N/A
- EPS
- THQ N/A
- MDXG 0.27
- Revenue
- THQ N/A
- MDXG $352,375,000.00
- Revenue This Year
- THQ N/A
- MDXG $9.55
- Revenue Next Year
- THQ N/A
- MDXG $11.43
- P/E Ratio
- THQ N/A
- MDXG $25.67
- Revenue Growth
- THQ N/A
- MDXG 5.34
- 52 Week Low
- THQ $15.29
- MDXG $5.47
- 52 Week High
- THQ $20.38
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- THQ 39.75
- MDXG 55.42
- Support Level
- THQ $16.93
- MDXG $6.37
- Resistance Level
- THQ $17.67
- MDXG $6.99
- Average True Range (ATR)
- THQ 0.31
- MDXG 0.32
- MACD
- THQ -0.04
- MDXG 0.03
- Stochastic Oscillator
- THQ 25.83
- MDXG 75.24
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.